Expired
Lead Plaintiff Deadline
Nov 24, 2020
Choose your preferred way to stay informed of new case launches and settlement deadlines
(i) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec, an investigational adenoassociated virus gene therapy, limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec’s durability of effect; (ii) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
In order to be eligible to join the BMRN class action lawsuit, you must have incurred a loss on shares of BioMarin purchased during the class period listed above.
If you suffered a loss in BioMarin during the relevant time frame or pursuant to the relevant offering(s), you have until November 24, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
TOP
